NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer

CX Ma, F Gao, J Luo, DW Northfelt, M Goetz… - Clinical Cancer …, 2017 - AACR
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …
被引用次数：309 相关文章

NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer

CX Ma, F Gao, J Luo, DW Northfelt… - Clinical Cancer …, 2017 - augusta.elsevierpure.com
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …
[HTML] nih.gov

[HTML][HTML] NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast …

CX Ma, F Gao, J Luo, DW Northfelt… - … cancer research: an …, 2017 - ncbi.nlm.nih.gov
Purpose Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …

NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer

CX Ma, F Gao, J Luo, DW Northfelt… - Clinical Cancer …, 2017 - mayoclinic.elsevierpure.com
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

CX Ma, F Gao, J Luo, DW Northfelt, M Goetz… - … Cancer Research: an …, 2017 - europepmc.org
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor-
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …

NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer

CX Ma, F Gao, J Luo, DW Northfelt… - Clinical Cancer …, 2017 - asu.elsevierpure.com
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer

CX Ma, F Gao, J Luo, DW Northfelt… - … : an official journal …, 2017 - pubmed.ncbi.nlm.nih.gov
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor-
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …

NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer

CX Ma, F Gao, J Luo, DW Northfelt… - Clinical Cancer …, 2017 - profiles.wustl.edu
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

CX Ma, F Gao, J Luo, DW Northfelt, M Goetz… - … Cancer Research: an …, 2017 - europepmc.org
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor-
positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …